{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:54:39Z","timestamp":1793084079145,"version":"4.5.0"},"reference-count":34,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>The polysymptomatic distress (PSD) scale is derived from variables used in the 2010 American College of Rheumatology (ACR) fibromyalgia (FM) criteria modified for survey and clinical research. The scale is useful in measuring the effect of PSD over the full range of pain-related clinical symptoms, not just in those who are FM criteria-positive. However, no PSD scale categories have been defined to distinguish severity of illness in FM or in those who do not satisfy the FM criteria. We analyzed the scale and multiple covariates to develop clinical categories and to further validate the scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>FM was diagnosed according to the research criteria modification of the 2010 ACR FM criteria. We investigated categories in a large database of patients with pain (2732 with rheumatoid arthritis) and developed categories by using germane clinic variables that had been previously studied for severity groupings. By definition, FM cannot be diagnosed unless PSD is at least 12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Based on population categories, regression analysis, and inspections of curvilinear relationships, we established PSD severity categories of none (0\u20133), mild (4\u20137), moderate (8\u201311), severe (12\u201319), and very severe (20\u201331). Categories were statistically distinct, and a generally linear relationship between PSD categories and covariate severity was noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>PSD categories are clinically relevant and demonstrate FM type symptoms over the full range of clinical illness. Although FM criteria can be clinically useful, there is no clear-cut symptom distinction between FM (+) and FM (\u2212), and PSD categories can aid in more effectively classifying patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.141519","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T21:12:55Z","timestamp":1434402775000},"page":"1494-1501","source":"Crossref","is-referenced-by-count":104,"title":["The Use of Polysymptomatic Distress Categories in the Evaluation of Fibromyalgia (FM) and FM Severity"],"prefix":"10.3899","volume":"42","author":[{"given":"Frederick","family":"Wolfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Walitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes J.","family":"Rasker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"H\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2015,6,15]]},"reference":[{"key":"2018112909343091000_42.8.1494.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"2018112909343091000_42.8.1494.2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20140"},{"key":"2018112909343091000_42.8.1494.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100594"},{"key":"2018112909343091000_42.8.1494.4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20156"},{"key":"2018112909343091000_42.8.1494.5","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21931"},{"key":"2018112909343091000_42.8.1494.6","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3182a8eb1f"},{"key":"2018112909343091000_42.8.1494.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep458"},{"issue":"Suppl 74","key":"2018112909343091000_42.8.1494.8","first-page":"88","article-title":"Hearing loss in fibromyalgia? Somatic sensory and non-sensory symptoms in patients with fibromyalgia and other rheumatic disorders","volume":"30","author":"Wolfe","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909343091000_42.8.1494.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.09.027"},{"key":"2018112909343091000_42.8.1494.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080897"},{"key":"2018112909343091000_42.8.1494.11","first-page":"1674","article-title":"Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"34","author":"Wolfe","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909343091000_42.8.1494.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq155"},{"key":"2018112909343091000_42.8.1494.13","doi-asserted-by":"publisher","DOI":"10.1097\/00006842-200203000-00008"},{"key":"2018112909343091000_42.8.1494.14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088740"},{"key":"2018112909343091000_42.8.1494.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"2018112909343091000_42.8.1494.16","first-page":"473","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"MedCare"},{"key":"2018112909343091000_42.8.1494.17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.50.6.613"},{"key":"2018112909343091000_42.8.1494.18","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.12179"},{"key":"2018112909343091000_42.8.1494.19","unstructured":"Corporation S . Stata statistical software: release 13.1. College Station: Stata Corporation; 2013."},{"key":"2018112909343091000_42.8.1494.20","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3"},{"key":"2018112909343091000_42.8.1494.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7549.1080"},{"key":"2018112909343091000_42.8.1494.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu169"},{"key":"2018112909343091000_42.8.1494.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130367"},{"key":"2018112909343091000_42.8.1494.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131171"},{"key":"2018112909343091000_42.8.1494.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-3074-3"},{"key":"2018112909343091000_42.8.1494.26","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.48"},{"key":"2018112909343091000_42.8.1494.27","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-012-0759-x"},{"key":"2018112909343091000_42.8.1494.28","doi-asserted-by":"publisher","DOI":"10.1186\/ar2783"},{"key":"2018112909343091000_42.8.1494.29","doi-asserted-by":"publisher","DOI":"10.1186\/ar3311"},{"key":"2018112909343091000_42.8.1494.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.05.002"},{"key":"2018112909343091000_42.8.1494.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100511"},{"key":"2018112909343091000_42.8.1494.32","first-page":"653714","article-title":"A comprehensive evaluation of standardized assessment tools in the diagnosis of fibromyalgia and in the assessment of fibromyalgia severity","volume":"2012","author":"Boomershine","year":"2011","journal-title":"Pain Res Treat"},{"key":"2018112909343091000_42.8.1494.33","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X10374437"},{"key":"2018112909343091000_42.8.1494.34","first-page":"728","article-title":"The fibromyalgia impact questionnaire: development and validation","volume":"18","author":"Burckhardt","year":"1991","journal-title":"J Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.141519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:54:34Z","timestamp":1543499674000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.141519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,15]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,1]]},"published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.3899\/jrheum.141519"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.141519","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,15]]}}}